The organising committee warmly invite you to join us in Melbourne for the 4th Annual Theranostics World Congress from 7-9 November. The theme for 2016 is If you can see it, you can treat it and the purpose of this conference is to educate, promote and support the application and use of radio-labelled agents in the diagnosis and treatment of cancer. Building on principles first established using radio-iodine for imaging and treatment of thyroid cancer, theranostics is entering an exciting phase of its evolution with new targets being identified and increasing evidence of the success and wider applicability of this approach. The conference will feature presentations on molecular imaging tracers that allow selection and prediction of response to radionuclide therapies as well as the latest information on radionuclide therapy trials.
The conference will feature presentations on molecular imaging tracers that allow selection and prediction of response to radionuclide therapies as well as the latest information on radionuclide therapy trials. This fascinating program will be supported by a respected and international panel of expert practitioners. (To learn more about the Australian and international speakers who have accepted invitations to share their expertise at the Congress please click here.)
The disease focus will be neuroendocrine tumours and prostate cancer with exciting and innovative theranostic advances being presented from around the globe. Updates on somatostatin receptor imaging and Peptide Receptor Radionuclide Therapy (PRRT) of neuroendocrine tumours and PSMA imaging and therapy of prostate cancer will be of particular interest to clinicians working with these diseases.
CEO Unicorn Foundation
Theranostics Convenor 2016
Professor Rodney J. Hicks,
MBBS (Hons), MD, MD, FRACP, FAHMS
Register and submit abstracts here for Theranostics 2016!